As vaccine manufacturers tackle increasingly intractable pathogens, vaccines will be developed that show efficacy, but that are less efficacious than established vaccines. Consequently, regulatory and public health authorities will be faced with difficult decisions about whether such vaccines should be recommended for implementation and, if so, under what circumstances. The RTS,S/AS01 malaria candidate vaccine provides an important example of such a challenge.
Original Source [2]
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/implementation-malaria-candidate-vaccine-rtssas01
[2] http://www.lancet.com/journals/lancet/article/PIIS0140-6736(15)00807-7/abstract
[3] http://admin.indiaenvironmentportal.org.in/category/author/brian-greenwood
[4] http://admin.indiaenvironmentportal.org.in/category/author/ogobara-k-doumbo
[5] http://admin.indiaenvironmentportal.org.in/category/journal/lancet
[6] http://admin.indiaenvironmentportal.org.in/category/thesaurus/malaria
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/vector-borne-diseases
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/vaccination
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/child-health
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[12] http://admin.indiaenvironmentportal.org.in/category/thesaurus/public-sector
[13] http://admin.indiaenvironmentportal.org.in/category/thesaurus/private-sector
[14] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drug-industry
